Back

Glycan-specific IgM is critical for human immunity to Staphylococcus aureus

Hendriks, A. M.; Kerkman, P. F.; Varkila, M. R.; Haitsma-Mulier, J. L.; Ali, S.; ten Doesschate, T.; van der Vaart, T. W.; de Haas, C. J. C.; Aerts, P. C.; Cremer, O. L.; Bonten, M. J.; Nizet, V.; Liu, G. Y.; Codee, J. D. C.; Rooijakkers, S. H.; van Strijp, J. A.; van Sorge, N. M.

2023-07-14 microbiology Community evaluation
10.1101/2023.07.14.548956 bioRxiv
Show abstract

Staphylococcus aureus is a major human pathogen but the immune factors that protect against it remain elusive. In particular, high opsonic IgG titers achieved in preclinical S. aureus animal immunization studies have consistently failed to translate to protection in human clinical trials. Here, we investigated the antibody responses to a conserved surface glycan, Wall Teichoic Acid (WTA). IgM and IgG antibodies specific to WTA were universally present in plasma from healthy individuals. Functionally, WTA-specific IgM outperformed IgG in opsonophagocytic killing of S. aureus and conferred passive protection against S. aureus infection in vivo. In the clinical setting, WTA-specific IgM responses, but not IgG responses, were significantly lower in S. aureus bacteremia patients compared to healthy individuals, correlated with mortality risk and showed impaired bacterial opsonization. Our findings can guide risk stratification of hospitalized patients and inform future design of antibody-based therapies and vaccines against serious S. aureus infection.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.